Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975624 | 0.92 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17371116 | 0.92 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21139430 | 0.92 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13966414 | 0.92 | PI4KA (0.61) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL21139458 | 0.90 | SLC29A1 (0.54) | CCNB2CDK1CCNB1CCNB3SLC29A1 | |
| SCHEMBL20434991 | 0.88 | SLC29A1 (0.48) | CCNB2CDK1CCNB1CCNB3SLC29A1 | |
| SCHEMBL20435009 | 0.88 | PI4KA (0.56) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26292145 | 0.88 | PI4KA (0.56) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL20435006 | 0.88 | PI4KA (0.56) | SLC29A1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19443155 | 0.88 | CCNB2 (0.47) | CCNB2CDK1CCNB1CCNB3SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2015-12-31 | — | — | US | disclosed |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | CCNB2 3474/4885CDK1 1493/4885CCNB1 3063/4885 |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | CCNB2 3474/4885CDK1 1493/4885CCNB1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.